EGFR exon 19 mutation	Non Small Cell Lung Cancer	EGFR exon 19 mutation	Non Small Cell Lung Cancer	erlotinib + ramucirumab Sensitive: B - Late Trials erlotinib + ramucirumab Sensitive : B	erlotinib + ramucirumab Sensitive: B - Late Trials erlotinib + ramucirumab Sensitive : B
EGFR exon 19 mutation	Non Small Cell Lung Cancer	EGFR exon 19 mutation	Non Small Cell Lung Cancer	icotinib Sensitive: B - Late Trials icotinib Sensitive : B	icotinib Sensitive: B - Late Trials icotinib Sensitive : B
EGFR exon 19 mutation	Non Small Cell Lung Cancer	EGFR exon 19 mutation	Non Small Cell Lung Cancer	erlotinib Sensitive: C2 – Inclusion Criteria erlotinib Sensitive : C2	erlotinib Sensitive: C2 – Inclusion Criteria erlotinib Sensitive : C2
EGFR exon 19 mutation	Lung Adenocarcinoma	EGFR exon 19 mutation	Lung Adenocarcinoma	bevacizumab + erlotinib Sensitive: C3 – Early Trials bevacizumab + erlotinib Sensitive : C3	bevacizumab + erlotinib Sensitive: C3 – Early Trials bevacizumab + erlotinib Sensitive : C3
EGFR exon 19 mutation	Non Small Cell Lung Cancer	EGFR exon 19 mutation	Non Small Cell Lung Cancer	gefitinib Sensitive: C3 – Early Trials gefitinib Sensitive : C3	gefitinib Sensitive: C3 – Early Trials gefitinib Sensitive : C3
EGFR exon 19 mutation	Lung Adenocarcinoma	EGFR exon 19 mutation	Lung Adenocarcinoma	erlotinib Sensitive: C3 – Early Trials erlotinib Sensitive : C3	erlotinib Sensitive: C3 – Early Trials erlotinib Sensitive : C3
EGFR exon 19 mutation	Non Small Cell Lung Cancer	EGFR exon 19 mutation	Non Small Cell Lung Cancer	cisplatin + gefitinib + docetaxel Sensitive: C3 – Early Trials cisplatin + gefitinib + docetaxel Sensitive : C3	cisplatin + gefitinib + docetaxel Sensitive: C3 – Early Trials cisplatin + gefitinib + docetaxel Sensitive : C3
EGFR exon 19 mutation	Non Small Cell Lung Cancer	EGFR exon 19 mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
EGFR exon 19 mutation	Non Small Cell Lung Cancer	EGFR exon 19 mutation	Non Small Cell Lung Cancer	afatinib Sensitive: C3 – Early Trials afatinib Sensitive : C3	afatinib Sensitive: C3 – Early Trials afatinib Sensitive : C3
EGFR exon 19 mutation	Non Small Cell Lung Cancer	EGFR exon 19 mutation	Non Small Cell Lung Cancer	FCN-411 Sensitive: C3 – Early Trials FCN-411 Sensitive : C3	FCN-411 Sensitive: C3 – Early Trials FCN-411 Sensitive : C3
EGFR exon 19 mutation	Lung Adenocarcinoma	EGFR exon 19 mutation	Lung Adenocarcinoma	osimertinib Sensitive: C3 – Early Trials osimertinib Sensitive : C3	osimertinib Sensitive: C3 – Early Trials osimertinib Sensitive : C3
EGFR exon 19 mutation	Pancreatic Adenocarcinoma	EGFR exon 19 mutation	Pancreatic Adenocarcinoma	erlotinib Sensitive: C4 – Case Studies erlotinib Sensitive : C4	erlotinib Sensitive: C4 – Case Studies erlotinib Sensitive : C4
EGFR exon 19 mutation	Small Cell Lung Cancer	EGFR exon 19 mutation	Small Cell Lung Cancer	osimertinib Sensitive: C4 – Case Studies osimertinib Sensitive : C4	osimertinib Sensitive: C4 – Case Studies osimertinib Sensitive : C4
EGFR exon 19 mutation	Non Small Cell Lung Cancer	EGFR exon 19 mutation	Non Small Cell Lung Cancer	osimertinib Sensitive: C4 – Case Studies osimertinib Sensitive : C4	osimertinib Sensitive: C4 – Case Studies osimertinib Sensitive : C4

EGFR exon 19 mutation

Associations